Effects of rokitamycin and other macrolide antibiotics on Mycoplasma pneumoniae in L cells | Zendy

Tomoko MISU | Zendy; S Arai | Zendy; Mayumi Furukawa | Zendy; Yoichi Yamamoto | Zendy; Teinosuke Miyazaki | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effects of rokitamycin and other macrolide antibiotics on Mycoplasma pneumoniae in L cells

Author(s) -

Tomoko MISU,

S Arai,

Mayumi Furukawa,

Yoichi Yamamoto,

Teinosuke Miyazaki

Publication year - 1987

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.31.11.1843

Subject(s) - josamycin , macrolide antibiotics , microbiology and biotechnology , erythromycin , antibiotics , mycoplasma pneumoniae , mycoplasma , ketolide , biology , microgram , medicine , pneumonia , in vitro , biochemistry

Fifty strains of Mycoplasma pneumoniae in L cells were tested for susceptibility to macrolide antibiotics. Rokitamycin, a new macrolide antibiotic, was most active against these organisms, with an MIC for 90% of strains of 0.007 microgram/ml. The MICs of erythromycin, josamycin, and kitasamycin for 90% of strains were 0.03, 0.03, and greater than or equal to 0.06 microgram/ml, respectively. Based on these results, rokitamycin is a promising antibiotic for the treatment of mycoplasmal infections, and further clinical investigations are needed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research